4571 — Nano Holdings Share News
0.000.00%
Last trade - 00:00Table: NanoCarrier - Q1 parent results
Brief: NanoCarrier signs exclusive agreement for global study on new approach of using NC-6004 to treat head and neck cancer
Brief: NanoCarrier signs joint-development contract with Ceolia Pharma
Brief: NanoCarrier says basic agreement on international joint development of NC-6004 to treat head and neck cancer
Table: NanoCarrier -2017/18 parent results
Brief: NanoCarrier says business and capital alliance with Gene Techno Science and Noritsu Koki
Table: NanoCarrier -2017/18 parent forecast
Table: NanoCarrier - 9-MTH parent results
Brief: NanoCarrier starts to discuss business alliance with Ceolia Pharma
Brief: NanoCarrier signs license preferential negotiating rights agreement with AccuRna
Table: NanoCarrier - 6-MTH parent results
Brief: VBL Therapeutics and Nanocarrier sign exclusive agreement for VB-111 in Japan
Brief: Nanocarrier signs exclusive agreement with VBL Therapeutics for VB-111 in Japan
Table: NanoCarrier -2017/18 parent forecast
Brief: NanoCarrier and JCR conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines
Table: NanoCarrier - Q1 parent results
Brief: NanoCarrier says orphan drug designation of NC-6004 by the U.S. FDA
Brief: NanoCarrier receives orphan drug designation from FDA
Brief: NanoCarrier announces licenses contract with Todai TLO